• Home
• About Us
• Careers
• Find a Physician
• Health Information
• Hospitals/Other Facilities
• Patient Services
• Programs and Services

Breast Cancer Study Available at John Muir Health:

Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial

This study involves the use of a new diagnostic test called the Oncotype DX Breast Cancer Assay to determine your recurrence score, which is the likelihood of your breast cancer returning or recurring.

Patients with determined intermediate risk will be the primary study group and will receive either hormonal therapy alone or hormonal therapy plus chemotherapy. Patients in the low risk group will receive hormonal therapy only and those in high risk will receive chemotherapy plus hormonal therapy. The purposes of this study are to determine whether patients with intermediate risk benefit from chemotherapy, and to confirm that patients with low risk may be cured with hormonal therapy alone and may not need chemotherapy to reduce their risk of recurrence.

To get more information or see if you qualify, please contact us:

John Muir Clinical Research Center
2550 Almond Ave, Suite 3
Concord, CA 94520
Phone: (925) 674-2580
Fax: (925) 674-2485
clinicalresearch@johnmuirhealth.com